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Abstract

PREPARATION AND CHARACTERIZATION OF AN ELECTROSPUN
GELATIN/DENDRIMER HYBRID NANOFIBER DRESSING
FOR CHRONIC WOUND TREATMENT
By Alicia Smith-Freshwater
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science in Biomedical Engineering at Virginia Commonwealth University.
Virginia Commonwealth University, 2009
Director: Hu Yang, Ph.D., Assistant Professor, Biomedical Engineering
A novel dendritic wound dressing was designed and characterized for its potential
to treat chronic wounds.

Comprised of gelatin, dendrimer, synthetic polymer and

antibiotics, the dressing was electrospun to mimic the natural extracellular matrix (ECM).
Gelatin is biocompatible, biodegradable, non-toxic, and easily available. The antibiotic,
doxycycline,

has

the

ability

to

inhibit

matrix

metalloproteinases.

Matrix

metalloproteinases, which occur in excess in chronic wounds, degrade the reconstituted
ECM.

Starburst™ polyamidoamine (PAMAM) dendrimer G3.5, which provides a

versatile and structurally controlled architecture to construct nanomedicine, was covalently
bonded to the gelatin backbone and electrospun into nanofibers with gelatin, doxycycline
and stabilizing polymers. The proposed gelatin/dendrimer hybrid provides a bacterial free

environment and mimics the ECM to promote wound healing. The development of this
new polymeric matrix is an important step in advancing the use of bioactive nanofibers
with targeted and controlled drug delivery as a wound dressing.

CHAPTER 1 Introduction

Chronic wounds, also interchangeably termed decubitus ulcers, are one of the
major health concerns worldwide. The occurrence of chronic wounds, which are prevalent
in elderly patients who are bedfast or patients with poor circulation, paralysis or
compromised immune systems, is on the rise.1

There are a number of causes for this

increased incident rate of chronic wounds. Medical advances have resulted in prolonged
and improved quality of life for quadric- and paraplegics, as well as individuals with
chronic illnesses like diabetes. The increasing elderly population and incidence of diabetes
mellitus provide the impetus to achieve cutting edge advances in the treatment and healing
of chronic wounds. 2
The treatment costs of patients with non-healing wounds are significant and
necessitate aggressive intervention. This intervention is imperative to decrease morbidity
and reduce treatment costs. Yet, the treatment of chronic wounds is both challenging and
complex, largely due to prolonged healing resulting from the extended chronic
inflammation phase of the wound healing process. This extended phase of chronic wound
healing results in infiltration of excessive amounts of neutrophils at the wound site.

3

Neutrophils produce matrix metalloproteinases (MMP), which are destructive proteolytic
enzymes responsible for degrading the ECM.4

Matrix metalloproteinases are also

essential to wound healing as they facilitate cell migration and new tissue formation. Too
much MMP-8 creates an imbalance and results in degradation of new/regenerated ECM.
1

Contemporary chronic wound dressings are designed to create and retain a moist
environment around the wound bed to facilitate wound healing.

5

Classified by

composition, wound dressings include hydrocolloids, alginates, and hydrogels in the form
of thin films or fibers, foam sheets and gelatins. Their use is augmented by medicated
creams and antibiotic ointments.
The proposed treatment protocol involves the fabrication and application of an
electrospun gelatin/dendrimer hybrid having PAMAM G3.5 and encapsulated therapeutic
drugs. PAMAM G3.5 is a highly branched structure with surface groups that are easily
modified. Doxycycline (DC) is an effective antibiotic with the added ability to inhibit
MMPs; thus facilitating wound healing.

6

Gelatin was selected as it is more readily

available than collagen. Further, gelatin has many attractive properties as a biomaterial
such as its biological origin, biodegradability, and biocompatibility.7

Four different

scaffolds were fabricated for this study. The control scaffold was gelatin [100 mg/mL],
and the three evaluation scaffolds were gelatin-dendrimer and encapsulated Doxycycline
electrospun with poly(-caprolactone), poly(glycolic acid) and poly(lactic-co-glycolic
acid), respectively.

A major objective of this study was to identify the critical parameters

to fabricate a gelatin/dendrimer hybrid with optimum fiber size, mechanical strength and
porosity to be used to treat chronic wounds. A secondary objective was to determine if
controlled drug release of DC could be achieved using the designed gelatin-dendrimer drug
delivery system.

2

CHAPTER 2 Background
2.1 Chronic Wounds
2.1.1 Normal Wound Healing
Wounds are the result of chemical, physical or thermal damage to the skin, blood
vessel or other bodily organ. 8

This damage manifests itself as a break or defect in the

skin, blood vessel, etc. Illnesses or physiological conditions, such as chicken pox or a
hematoma, can also result in a wound. Regardless of whether the damage to the skin is the
result of a cut, tear, puncture or contusion from blunt force trauma, the body’s response to
the injury is convoluted yet systematically organized.
Normal wound healing is usually described using four distinct phases beginning
with (1) hemostasis, (2) inflammation, (3) proliferation and (4) remodeling.

9

Hemostasis

involves clotting to stem bleeding via a temporary fibrin blood clot. The second phase
involves acute and chronic inflammation. Acute inflammation is of short duration and
primarily involves phagocytosis of microorganisms and foreign materials by neutrophils.
Exudation to provide an influx of fluid, plasma proteins and blood cells to the injured
tissue site is also a major activity in acute inflammation.

Chronic inflammation is

characterized by continued phagocytosis via macrophages that also induce the release of
neutral proteases, chemotactic factors, reactive oxygen metabolites and growth factors.
Connective tissue and blood vessel proliferation is also initiated. In the proliferation
phase, transforming growth factor beta (TGF-) yields increased transcription of genes for
synthesis of collagen, proteoglycans and fibronectin; but most importantly decreases the

3

protease responsible for the breakdown of matrix proteins.

10

The final phase,

remodeling, is characterized by the synthesis and degradation of ECM components to
establish a new equilibrium.
2.1.2 Chronic Wounds and Matrix Metalloproteinases
Chronic wounds represent a significant cause of morbidity and mortality for adult
patients experiencing diabetes, cancer, malnutrition, physical disabilities (e.g. paralysis),
and compromised immunity due to illnesses like HIV/AIDS. 11

Non-healing wounds do

not progress through the stages of normal wound healing due to the self-sustaining cycle of
chronic inflammation leading to the destruction of the ECM. 12 Matrix metalloproteinases
are enzymes that are involved in tissue reorganization, inflammation and remodeling.
Sixteen MMPs have been identified and characterized for substrate specificity.

13

Failure of MMP regulation has been correlated with deficient wound healing, such as
chronic wound healing.

Chronic non-healing ulcers were characterized by significantly

higher levels of MMP-1 and MMP-8 and lower levels of tissue inhibitor of
metalloproteinase 1 (TIMP-1) in a comparison of chronic non-healing ulcers to normal
healing wounds. Studies have shown that the over-expression and activation of neutrophilderived MMP-8 is involved in the pathogenesis of nonhealing chronic ulcers. 14
Wounds are classified as either acute or chronic. Acute wounds usually result from
disruption to the tissue, yet heal completely in the expected time-frame of eight to 12
weeks, and with minimal scarring12. However, chronic wounds that develop from tissue
injuries are slow to heal, and have not healed within the expected 12 week timeframe.
4

Chronic wound healing is impeded by repeated tissue insults or underlying physiological
conditions like diabetes, poor blood circulation or persistent infections15. Chronic wounds
are impeded by extended inflammation where the balance of ECM degradation and
synthesis is compromised by the excessive amounts of neutrophils thus generating
increased levels of MMPs.

Figure 1 is a schematic adapted from Nwomeh et al.,

summarizing key differences in normal and chronic wound healing.

12

As noted in the

diagram, the amount of neutrophils increases, therefore increasing matrix degradation due
to MMP. Additionally, protease inhibitors are decreased, which allows even further matrix
degradation.

The degradation occurs not only of the damaged ECM and tissue, but

reconstituted matrix is also degraded.
Figure 1: Normal versus Chronic Wound Healing
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2.1.3 Healing and Treatment
The majority of chronic wounds are pressure ulcers (bed stores), diabetic foot
ulcers and venous stasis ulcers, with the latter accounting for 70% of chronic wounds. 16
A pressure ulcer is a break in the skin and is commonly located in the posterior and ischial
sections of the pelvis, the heel or the upper part of the femur. Pressure ulcers are caused by
ischemia that occurs when pressure on the tissue is greater than the pressure in capillaries,
thus restricting blood flow into the area.

17

They occur due to friction and external

pressure in the elderly, and patients that are bed-ridden or have spinal cord
injuries/paralysis.

Chronic wounds develop in four distinct stages.

18

These four stages

influence the treatment protocol and are listed in Table 1.
Table 1: Four Distinct Stages of Chronic Wound Progression
Stage

General Characteristics

Stage I

Reddened area on the skin; no break. Non-blanchable when pressed; and
coloration is pink, red, or mottled after pressure is relieved. Patients with
darker pigmentation have subtle purplish or extra discoloration.

Stage II

Partial loss of skin thickness. Skin blisters and forms an open sore. The
area is broken, cracked, blistered, and mottled in color. Necrotic tissue or
drainage may also be present.

Stage III

Full loss of skin thickness. Skin breakdown (i.e. crater); tissue damage
may be necrotic (black), draining (yellow), or granulating (red).

Stage IV

Deep pressure ulcer, muscle, bone tendon or joint damage. Damage may
have extensive drainage and necrotic tissue.

6

Current and emerging chronic wound treatments are designed to alleviate some of
the causes responsible for delayed healing. Methods for wound repair include mitigation
of the primary causes like external pressure, ischemia, bacterial load and protease
imbalance.

The application and use of antibiotics and antibacterial agents, debridement,

irrigation, vacuum-assisted closure, oxygenation, moist wound healing and addition of
cells and growth factors are various methods used to advance healing of chronic wounds. 19
The treatment protocol for Stage I pressure ulcers involves decreasing or
eliminating the external pressure source, reducing moisture from incontinence, employing
pressure relief devices, and ensuring adequate patient hydration and nutrition. To prevent
bacterial invasion, transparent film, foam or hydrocolloid dressings are applied.20

The

primary function of the temporary dressings is to serve as a barrier, much like human skin.
Dressings to treat Stage II ulcers are principally designed to keep the peri-ulcer skin dry
while maintaining a moist wound bed. Topical antibiotics and antibacterials like silver
sulfadizine, doxycycline or triple antibiotic are applied to cure or prevent infection. 21-22
Debridement, irrigation, and warming are also employed to decrease bacterial load. The
healing of chronic wounds is further compromised by the failure of fibroblasts to produce
adequate ECM proteins.

23

Various methods exist to balance proteases through

implantation of cells, growth factors, hormones and other materials to secrete or enhance
healing.

Wound pain management through use of analgesics and vitamin and mineral

supplementation is also important in the resolution of chronic wounds.

Bromelain,

vitamins A, C and E, zinc, and glucosamine are some of the supplemental vitamins and
minerals used to promote wound healing.
7

2.2 Dendrimers for Drug Delivery
Dendrimers are an inimitable class of polymeric nanoparticles that play key roles in
emerging nanotechnology, biotechnology, and nanomedicine. Dendrimers are spheroid or
globular nanostructures that are precisely engineered to carry molecules encapsulated in
their interior void spaces or attached to the surface. 24

Dendrimers are attractive in the

field of nanomedicine as drug carriers for reasons such as:
1. Low polydisperity index
2. Multiple attachment sites
3. A well-defined, controllable size
4. A highly-branched globular structure that can be easily modified to change its
chemical properties.
5. Capability of drug encapsulation in the core of the dendrimer as well as
dendrimer-drug conjugation by drug attachment to the surface of the dendrimer.
The use of dendrimers for drug delivery and controlled drug release improves drug
efficacy. Controlling the release time and delivery location of therapeutic drugs allows
sustained and targeted drug delivery in the therapeutically desirable range; thus
contributing to lower drug dosages and a reduction of harmful side effects.
2.2.1 Structure of PAMAM Dendrimers
Dendrimers are large, complex macromolecules with well defined and consistent
size and form. Their highly branched, three-dimensional architecture consists of a core,
branches and end groups. Figure 2 is a schematic of a PAMAM (G2) dendrimer.

8

Figure 2: Chemical Structure of PAMAM (G2.0) Dendrimer

Core
Surface group

Branches

Size, shape, and reactivity of dendrimers are determined by generation (branch levels) and
chemical composition of the core, interior branching, and surface functionalities. The
terminal groups heavily influence the chemical properties of the molecule and physical
properties such as solubility and viscosity.

25

Dendrimers with hydrophilic surface

groups are soluble in polar solvents and vice-versa. In solution, linear polymer chains
exhibit flexible coils and dendrimers in comparison reflect a tightly coiled ball affecting
their viscosity.
The multi-functionalized core of the dendrimer forms the central point of the
molecule. The monomer chains that branch out from the core are termed the first
generation, (G1.0); where the generation increases for every two monomer branches.
Dendrimer surface area and size of the molecule increases with each generation- until the
effect of steric hindrance prevents continued growth (branching). Dendrimers become
9

densely packed as they extend out to the periphery forming a closed membrane-like
structure. At this juncture, dendrimers are said to have reached a critical branched state
called the “starburst effect”. 25 The starburst effect is witnessed after the tenth generation
for PAMAM dendrimers.
The shape of the dendrimer is determined by its generation. Dendrimers of lower
generations (G0-2) are asymmetrically shaped and contain more inner void space (internal
cavities) as compared to higher generations.

Higher generation dendrimers (G4 and

greater) are globular shaped. 26
2.2.2 Synthesis of PAMAM Dendrimers
Dendrimers are constructed through a set of repeating chemical synthesis
procedures that build up from the molecular level to the nanoscale region. Dendrimers are
generally prepared using divergent or convergent methods. Both methods involve iterative
sequences in which each iteration leads to a higher generation dendrimer. In the divergent
method, the dendrimer grows outward from a multifunctional core. The core reacts with
monomers containing one reactive and two dormant groups giving rise to the first
generation. 26

The dendrimer diameter increases linearly whereas the number of surface

groups increases geometrically. Disadvantages of the divergent method are side reactions
and incomplete reactions of the end groups causing defects in the dendrimer structure.
Additionally, the divergent method requires a large excess of reagents to drive reactions to
completion and prevent side reactions. This makes purification more difficult.

10

The convergent method resolves difficulties in the divergent method of dendrimer
synthesis. The convergent method sequentially builds the dendrimer from the end group
inwards. The method is initiated with the attachment of growing branched polymeric arms
(dendrons) to a multifunctional core molecule. Advantages of this approach include easy
end-product purification and minimal defects. The convergent method is limited in that
steric problems occur in the reactions of the dendrons and core molecule.

26

PAMAM dendrimers were the first dendrimers synthesized by Donald Tomalia and
co-workers in the 1980’s. Ammonia is used as the core molecule. 27 In the presence of
methanol, ammonia reacts with methyl acrylate then ethylenediamine is added.

This

allows ethylenediamine to also be used as a core molecule. The free amino group at the
end of each branch reacts with two methyl acrylate monomers and two ethylenediamine
molecules to form successive generations. Half-generation PAMAM dendrimers have
tertiary anionic carboxylate groups; and for full generation have cationic amino terminal
groups.
2.2.3 Drug Delivery Mechanisms
Drug delivery systems are employed to increase the efficacy of therapeutic drugs
through locally targeted and sustained release of a drug over time. Two common drug
delivery systems are liposomes and polymeric systems, yet both are limited.

Linear

polymers are polydisperse; therefore the molecular weight distribution impacts in vivo
biodegradation.

Liposome-based systems have poor stability and difficulty targeting

specific tissues.
11

Three main paradigms employed for dendrimer drug delivery are drug
encapsulation, dendrimer-drug conjugation and lyposomes.

Encapsulation of drugs uses

the steric bulk and internal cavities for entrapping hydrophobic drugs at the core.
Dendrimer-drug conjugates are generated via covalent attachment to the dendrimer surface
groups.

For example, dendritic unimolecular micelles can be fabricated through

PEGylation on the dendrimer surface.

26-28

PEGylation stabilizes the entrapped drugs,

provides additional sites to retain more drugs and increases the solubility of the entrapped
drugs.
Regardless of the drug carrier design, the ideal drug delivery system should be
inert, biocompatible, achieve high drug loading and increase solubility at physiological
conditions. The use of PAMAM dendrimers for the design of drug delivery systems is
largely due to desired in vivo biological properties such as non-toxicity and nonimmunogenicity . 26
2.3 Poly ( - hydroxy esters)
Poly(-hydroxy esters) are the most commonly used synthetic polymers in tissue
engineering applications.

29

As a biomaterial, poly (α-hydroxy esters) such as poly(-

caprolactone) (PCL) , poly(glycolic acid) (PGA) and the copolymer poly(lactic-co-glycolic
acid) (PLGA), are desirable for their biocompatibility and biodegradation properties.
Electrospinning the aforementioned synthetic polymers with natural polymers like
collagen, gelatin, elastin, etc., increases the mechanical integrity and strength of the fibrous
scaffold.

The biocompatibility of PGA, PLGA, and PCL copolymers, affirms their
12

preference as tissue engineered (TE) scaffold applications as they minimize the chronic
foreign body reaction and facilitate tissue regeneration. 30
The general selection criteria for the polymers used for this study was based on the
mechanical properties and the time of degradation. Key polymer properties are listed in
Table 2. Some of the benefits of the polymers used in this study are as follows:


Mechanical properties that remain strong until surrounding tissue has healed.



Do not invoke an inflammatory or toxic response.



Metabolized in the body after fulfilling their purpose, leaving no trace.



Easy processing into final product form.

Table 2: Polymer Properties
Polymer

Melting Glass-Transition Modulus
Point (°C)
Temp (°C)
(Gpa)a

Crystallinity
(%)

Degradation
Time
(months)b

PCL

58—63

(-65)— (-60)

0.4

30-70

>24

PGA

225—230

35—40

7.0

50

3 to 6

PLGA 85:15

173—230

40—60

0.2

Amorphous

6 to 12

(ratio dependent)

a) Tensile or flexural modulus.

b) Time to complete mass loss.

2.3.1 Poly(ε-caprolactone) (PCL)
Poly(ε-caprolactone) is a biodegradable polyester prepared by ring opening
polymerization of ε-caprolactone. Because PCL is degraded by hydrolysis of its ester
linkages in physiological conditions, it has received extensive interest for construction of
13

implantable biomaterials and drug delivery devices. The ring-opening polymerization of caprolactone yields a semi-crystalline polymer with a melting point of 59—64°C and a
glass-transition temperature of -60°C.
months.

31

Biodegradation of PCL in vivo can take up to 30

Because the homopolymer has a degradation time greater than 2 years,

copolymers have been synthesized to accelerate the rate of bioabsorption. PCL has been
commercially developed as a resorbable suture, adhesion barrier, and used for TE
scaffolds. 32 PCL beads are also used to encapsulate drugs for targeted and controlled drug
release.
2.3.2 Poly (glycolic acid) (PGA)
Poly(glycolic acid) is a biodegradable, thermoplastic polymer and the simplest
linear, aliphatic polyester. Poly(glycolic acid) is usually prepared by polycondensation or
ring-opening polymerization.

33

Mostly soluble in highly fluorinated solvents like

hexafluoroisopropanol (HFIP), high MW PGA polymer has been used in melt spinning,
electrospinning and film preparation.

Poly(glycolic acid) undergoes hydrolytic

degradation in physiological environments; which is augmented by enzymatic breakdown
through esterase activity. Poly(glycolic acid) degrades into glycolic acid, which is a
naturally occurring byproduct in the metabolic pathway. As such, glycolic acid is non
toxic and excreted in urine and as water and carbon dioxide. 32

In vivo degradation of

biomaterials synthesized with PGA is usually short; and degrades within seven days.
Previous experimental studies of sutures made with PGA showed a 50% loss in material
strength after two weeks; and complete loss of strength after four weeks. 34
14

One of the first biomedical applications for PGA was as a resorbable suture
marketed in 1962 as Dexon™.

35

Because PGA yields strong fibers that degrade into

water soluble monomers- it has found widespread use in surgical applications. Implantable
medical devices (e.g. rings, pins, rods, plates, screws, etc.) are also produced with PGA.
The use of PGA as a biomaterial has evolved to fabrication of TE scaffolds and for
controlled drug delivery.
2.3.3 Poly (lactic-co-glycolic acid) (PLGA)
Poly(lactic-co-glycolic acid) is a copolymer synthesized by ring-opening copolymerization of two different monomers, the cyclic dimers (1,4-dioxane-2,5-diones) of
glycolic acid and lactic acid. 36

Successive monomer units of glycolic acid and lactic acid

are linked together via ester bonds to form PLGA during polymerization.

Different

compositions of PLGA can be formed by altering the ratio of lactide to glycolide. For
example, PLGA 85:15 is comprised of 85% lactic acid and 15% glycolic acid. PLGA can
be dissolved by general solvents, such as tetrahydrofuran, acetone, chlorinated solvents
and ethyl acetate. 37
In the presence of water and in physiologic conditions, PLGA degrades by
hydrolysis of its ester linkages. The degradation rate is dependent on the monomer ratios.
The more glycolic acid units present, the higher the polymer solubility thus resulting in
faster degradation.

An exception to this rule is the copolymer with a 50:50 monomers'

ratio, which exhibits the faster degradation (about two months). 37
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The in vivo degradation of PLGA yields the original monomers, lactic acid and
glycolic acid. Lactic acid and glycolic acid are by-products of various metabolic pathways
in the body. 36 As a result, the use of PLGA for drug delivery and biomaterial applications
causes minimal toxicity.

The ability to regulate polymer degradation rate by controlling

the polymer monomer composition makes the use of PLGA in biomaterial applications
highly appealing. PLGA is used to construct various biomaterials like grafts, sutures,
implants, prosthetic devices, and micro and nanoparticles.
2.4 Wound Dressings
Wound dressings play an essential role in the treatment and healing of chronic
wounds. Key functions of dressings for healing chronic wounds include:

1. Protecting the ulcer from further injury,
2. Preventing infection and invasion of bacteria and other germs,
3. Maintaining the proper environment for healing,
4. Filling in the wound’s void space.

Wound dressings, unlike gauze or bandages, aid normal healing by maintaining moisture
in the wound bed. A chronic wound has a better chance of healing when the moisture level
is similar to that of healthy skin.

Wound dressings are classified based on their function

in the wound, material type, physical form and contact layer level.
highlighted in Table 3.
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Categories are

Table 3: Various Categories to Classify Dressing Type
Category

Different Classes

Wound Function

debridement, antibacterial, occlusive, absorbent, adherence

Material Type

hydrocolloid, alginate, collagen, hydrogel, etc.

Physical Form

ointment, film, foam, gelatin

Contact Layer

primary dressing (direct wound contact), secondary dressing
(cover primary dressing), island dressing (have a central
absorbent region surrounded by an adhesive portion)

2.4.1 Traditional and Emerging Dressings
Wound dressings have evolved over the years from mere coverings (plant herbs,
cotton wool, bandages and gauze) to bioactive, tissue-engineered (TE) scaffolds that
dispense therapeutic agents in a controlled manner and facilitate tissue regeneration via
interaction with cells.

Disadvantages of conventional dressings (e.g. cotton wool, gauze)

for treating chronic (open) wounds include delayed wound healing and generation of more
damage. 39 Gauzes are mainly used in chronic wounds as packing stuff to absorb fluid and
exudates; thus drawing fluid away from the wound. Some of the major disadvantages of
using traditional dressings for chronic wound management include:
1. Loss of bacterial protection when the outer surface of the gauze dressing
becomes moistened by wound exudates or external fluids.
2. Adherence of the dressing to the wound as fluids decrease. The dressing
becomes painful to remove and dries out the wound.
3. Requirement of frequent change out which diminishes patient compliance.
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Contemporary dressings have been developed to address the shortfalls of traditional
dressings. One of the most widely used dressings for chronic wounds are hydrocolloids. 38
They are designed to be used for light to moderately exuding wounds such as pressure
sores, leg ulcers, minor burns and traumatic injuries.

Hydrocolloid dressings are

impermeable to water vapor in their intact state. However, upon absorption of wound
exudates, the physical state of the dressing transforms to a gelatin. As the gelatin forms, it
becomes more permeable to water and air. 40 The gelatin is not painful to remove, thus
contributing to its popularity as a pediatric dressing.

Table 4 summarizes the top

dressings used to treat chronic wounds, as well as some of the advantages and
disadvantages of each. 41
A new generation of bioactive and medicated wound dressings that mediate and
regulate cell interaction are currently being developed, which is the focus of this study.
This milestone evolution advances the following in wound care management:
1. The fabrication of wound dressings from natural or biodegradable synthetic
polymers (collagen, gelatin, chitosan, PGA, PLGA, PCL) that mimic the tissue
matrix thus promoting cell attachment and proliferation.
2. The application of medicated TE scaffolds that yield targeted and controlled
release of antibiotics, antimicrobials, vitamin and mineral supplements and
growth factors that accelerate wound healing.
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Table 4: Different Dressings for Chronic Wound Management
Dressing
Hydrocolloids

Advantages

Disadvantages

Impermeable to bacteria

Impermeable to oxygen

(light to moderate exudates) Can be left in place for up to 7 Cannot handle heavily
days without changing
exudating wounds

Hydrogels
(dry and painful wounds)

Gelatin creates moist wound
bed

Gel & smell phenomenon

Soothing to patient

Need frequent changing

Maintains intimate contact
with the wound surface

Heavily exudating wounds
causes leakage

Creates moist environment for Cost
cell migration
Alginates

Highly absorbent

Fibrous debris, lateral wicking

(moderate to heavy
exudates)

Readily biodegradable; form
gelatin upon exudates
absorption

Requires moisture to function;
thus cannot be used for dry
wounds

Impermeable to bacteria
Foams

Absorbent

Smelly, malodorous discharge

(light to moderate exudates)

Occlusive

Opaque

Thermal insulation
Change every 3 days

2.4.2 Electrospun Gelatin/Dendrimer Hybrid with Doxycycline
Natural and synthetic polymeric wound dressings not only cover and protect the
wound from bacteria and further damage, they can also serve as drug delivery systems and
bioactive platforms to facilitate tissue growth. Upon hydration by the wound exudates,
19

drug delivery is achieved via hydrolysis, diffusion or gelatin formation and release
followed by degradation of the dressing/erosion of the gelatin.

The localized and

controlled release of antibiotics is preferred over systemic delivery as it allows direct
targeting of the wounded area and metered drug administration over an extended period of
time.
Doxycyline has been selected as the antibiotic to include in this study. It is an
effective antibiotic that has the ability to inhibit the degradative enzyme, MMP.

6

Doxycycline is a member of the tetracycline antibiotics group, commonly used to treat
infections. Tetracyclines work by inhibiting protein synthesis in bacteria by binding to the
30S ribosome, immobilizing the progressive translation of proteins thus preventing
reproduction.

It is hoped that this mechanism of action will mitigate the formation of

biofilms that routinely develop in chronic wounds. Doxycycline is frequently used to treat
inflammation of the prostate, respiratory and urinary tract infections, syphilis, pelvic
inflammatory disease, acne and Lyme disease.42 It is also used to prevent and treat
infections from E. Coli and methicillan-resistant Staphyloccus aureas (MRSA).
Tissue-engineered scaffolds are used to direct the growth of cells that are either
seeded within the porous structure of the scaffold or migrating from surrounding tissue.

43

The regeneration of tissue, i.e. wound healing, can also be supported by growth factors and
supplements that are contained in the dressing.

Electrospinning is recognized as an

efficient processing method to manufacture TE scaffolds that mimic native ECM.

44

The

originality of the proposed wound dressing is based on combining these technologies to
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design an electrospun gelatin/dendrimer hybrid for the treatment of chronic ulcers.
Uniqueness of the proposed dressing includes:
1. Fabrication of an electrospun drug delivery platform made from the natural
biopolymer gelatin (denatured collagen).
2. Nano-electrospinning gelatin with copolymers PGA, PLGA, and PCL to
enhance mechanical strength and ensure biodegradability.
3. Controlled and targeted drug release of Doxycycline that facilitates wound
healing as an antibiotic and by inhibiting the degradative enzyme,MMP.
The advantages and disadvantages of the proposed dressing compared to dressings
currently on the market are summarized in Table 5.
Table 5: Proposed versus Contemporary Wound Dressings 41
DRESSING
Foams

Hydrogels








Hydrocolloids

Proposed
Dressing








ADVANTAGES
Highly absorbent
Debrides wound
Comfortable & conformable
Soothing to patient
Intimate contact with wound
surface
Creates moist environment for
cell migration
Impermeable to bacteria
Can be left in place for
extended periods of time
Gel creates moist wound
Controlled release of
therapeutic drugs
Inhibition of destructive
enzymes (MMP)
Maintains moist wound bed
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DISADVANTAGES
Requires secondary dressing
Cost
Cannot be used on dry wounds
Need frequent changing
Cost
Cannot handle heavily
exudating wounds without
leakage
Impermeable to oxygen
Cannot handle heavily
exudating wounds
Gel & smell phenomenon
Pure electrospun gelatin is
mechanically weak
Required to cross-link or
electrospin with stabilizing
polymers (PCL, PGA, PLGA)

CHAPTER 3 Experimental Materials and Methods

3.1 Materials
Table 6: List of Materials
Material

Abbreviation

1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide
4-dimethylaminopyridine
4-nitro phenyl chloroformate
Chloroform
De-Ionized Water
Deuterium oxide
Dichloromethane
Dimethylformamide
Doxycycline
Ethanol (denatured)
Ethyl ether (anhydrous)
Hexafluoroisopropanol
Hydrochloric Acid
N,N-Dicyclohexylcarbodiimide
N-Hydroxy Succinimide
Ninhydrin
Poly (Glycolic Acid)
Poly (Lactic-Co-Glycolic Acid) (85:15)
Poly(ε-Caprolactone)
Porcine type-A gelatin
Sodium carbonate
Starburst™ G3.5 PAMAM dendrimer
Tetrahydrofluran
Triethylamine

EDC
DMAP
NPC
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DI water
D2O
DCM
DMF
DC
HFIP
HCl
DCC
NHS
PGA
PLGA
PCL
Gelatin
NaHCO3
G3.5
THF
TEA

3.2 Equipment

Table 7: List of Equipment
Name

Purpose

MTS Bionix 200®
Mechanical Testing System

Measure the tensile properties (stress, elongation) of
electrospun fibers.

Scanning Electron Microscope
Model 550

Photographs of scaffolds (characterize morphology and
fiber diameter using ImageTool™).

Eppendorf Centrifuge Model:
5415D

For Centrifugation, separation of the suspended phase
form liquid phase.

Freeze Dry System – Labconco
Model 77550

Freeze dry system to dry the frozen samples.

Nuclear Magnetic Resonance
(NMR)

Proton NMR measurement was performed on a 300
MHz NMR spectrometer.

Permeability Test Mechanism

Designed and fabricated by Scott Sell to measure
permeability (see section 3.4.6).

Ultra Violet – Visible (UV-Vis)

Quantitative analytical tool for Ninhydrin assay and
release experiments.

Spectrophotometer Genesys 6
UV Radiation source

UV light source, 90 W high-pressure mercury vapor
filled lamp, manufactured by Phillips (Holland).

Weighing Balance

For measuring the required amount of materials.
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3.3 Synthesis
3.3.1 Conjugation of Gelatin to PAMAM Dendrimer G3.5
The reaction synthesis for conjugating PAMAM G3.5 to gelatin is represented in
Figure 3. The reaction was carried out in three phases: formulate the gelatin solution,
activate the terminal carboxyl groups of the dendrimer and lastly, conjugate dendrimer to
gelatin.

The gelatin solution was prepared by weighing and adding 20 mg of gelatin (type

A Porcine powder) to 20 mL of sodium carbonate (pH 8.5). The mixture was stirred at
80°C until the solution was clear.
Figure 3: Conjugation Reaction of Gelatin to G3.5 Dendrimer
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Conjugation of gelatin to G3.5 involved the activation of the carboxyl (-COOH)
groups of the dendrimer using EDC chemistry to form a stable amide bond. Prior to the
reaction, 0.75 μmol of PAMAM G3.5 was dried via rotary evaporation to remove the
storage solution (i.e. methanol). The obtained dry product was then dissolved in 2 ml of DI
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water; added in 1mL increments and vortexed to ensure complete removal of PAMAM
G3.5 from the evaporator flask and transferred to a scintillation vial. PAMAM G3.5 has
64 carboxyl surface groups (S.G.). 45
activate half (32) of the surface groups.
subsequent drug attachment.

The EDC reagent was kept at a minimum to only
The remaining surface groups were reserved for

To this solution, 3mg of NHS and 5mg of EDC were added

and then stirred for 24hr at room temperature for activation of the surface groups. The
activated G3.5 solution was mixed with the gelatin solution and stirred in an ice bath for 4
hr. The salt was removed by centrifugation. The supernatant obtained was then added
drop-wise to 50 mL of cold ether and kept at -8 ºC for 24 hrs. The precipitate was collected
and then dried via rotary evaporation.

Rapid dialysis (12-14000 MWCO dialysis tubing;

DI water as the filtrate) was carried out to remove un-reacted NHS and EDC for
purification of the product. The recovered product was lyophilized for 24 hr to dry the
sample and then weighed.

3.3.2 Conjugation of Doxycycline to PAMAM Dendrimer G3.5
Conjugation of DC to PAMAM G3.5 involved the activation of carboxyl (-COOH)
groups of the dendrimer using HCl. Prior to the reaction, 0.75μmol of PAMAM G3.5 was
dried via rotary evaporation. The obtained dry product was then dissolved in 1 ml of DI
water. The solution was acidified with three to four drops of 1 N HCl (pH=1.0). The
acidified solution was dried again by rotary evaporation and then re-dissolved in 2 ml of
DMF (added at 1mL increments, vortexed and transferred to a scintillation vial). To this
solution, 15mg of DC, 8.5mg of DCC and 3.4mg of DMAP were added. The solution was
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stirred for 14 hrs at 4 ºC in an ice bath. After stirring, the solution was added drop wise to
40 mL of cold ether and kept at -40 ºC for 24 hrs to precipitate the salt (DCU). The mixture
was centrifuged to remove the precipitate. The supernatant was dried by means of rotary
evaporation. After drying, dialysis- with DI H2O as the filtrate, was performed to remove
non-reacted DCC and DMAP for further purification of the product. The recovered
product, G3.5 conjugated to DC, was analyzed by 1H-NMR. We could not confirm the
synthesis of DC to PAMAM G3.5. As this reaction did not yield the desired result, DC
was encapsulated in the spinning solutions and electrospun into a gelatin/dendrimer hybrid.

Figure 4: Proposed Conjugation Reaction of DC to G3.5 dendrimer
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3.3.3

Encapsulation of Doxycycline
Twenty milligrams of DC powder and 10 mg of PAMAM G3.5 were measured and

dissolved in 5mL of HFP along with various weight ratios of gelatin and the polymers
included in this study. It was assumed that as the melt polymer solutions were ensured to
be homogenous prior to electrospinning, that DC and PAMAM G3.5 would also be evenly
distributed with the other contents (gelatin and synthetic polymers) in the electrospun mat.
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3.3.4

Polymer-Gelatin Spin Dope Solutions
Solutions of 100 wt % gelatin, 50/50 (w/w) and 70/30 (w/w) PCL/gelatin, 50/50

(w/w) and 70/30 (w/w) PGA/gelatin and 50/50 (w/w) and 70/30 (w/w) PLGA/gelatin were
prepared by dissolving 500mg total in 5mL of HFIP in a glass scintillation vial. All
reagents were purchased from Sigma Aldrich Corporation and the synthetic polymers were
purchased from Lakeshore Biomaterials. Solutions were mixed for 24h on a shaker plate
to ensure complete dissolution to form a homogenous solution. The solutions were loaded
into a 5 mL Beckton Dickinson syringe and placed in a KD Scientific syringe pump
(Model 100) for electrospinning.
3.3.5

Electrospinning
Electrospinning is a type of extrusion type fiber fabrication method that employs

the use of an electrical charge to product micro and nano-scaled fibers from a liquid. The
experimental setup used for the electrospinning process is schematically shown in Figure
5.

To form fibers during electrospinning, a polymer solution is loaded into a syringe and

forced to the needle tip by a syringe pump. A positively charged electrode is attached to
the needle and when voltage is applied, a static electric field is created causing the droplet
of polymer at the end of the syringe to be stretched into a conical shape known as the
Taylor cone. With increasing electrical field, the discharged polymer solution jet is
elongated and whipped continuously by electrostatic repulsion causing the solvent to
evaporate.

The charged polymer fiber is deposited on a grounded collector.

For this

study, an adjustable high voltage power supply (Spellman CZE1000R; Spellman High
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Voltage Electronics Corporation) was used to apply a 25kV voltage to a blunt tip 18 gauge
needle fixed to the solution containing syringe. The negative electrode was connected to a
metallic lab rack with its circular plateau wrapped in aluminum foil. The spin solution was
delivered via a syringe pump controlling the mass flow rate to 3.5 mL/hr. Solutions were
electrospun onto a flat, stainless steel, grounded mandrel (2.5 x 10.2 x 0.3 cm) placed
approximately 12 cm from the needle tip and rotated at 500 rpms with back and forth
traversing to produce a scaffold of randomly oriented fibers; evenly distributed along the
collector mandrel. Upon completion of the spinning process, the scaffolds were removed
from the mandrel (sides slit; then gently peeled); and placed in the fume hood for
degassing and removal of HFIP. Samples were then stored for 24h in the dessiccator to
ensure moisture removal.
Figure 5: General Electrospinning Apparatus

Metering Pump

3.4 Characterization
3.4.1

Ninhydrin Assay
Verification of the conjugation of gelatin to G3.5 was indirectly determined by

measuring the remaining amine surface groups of gelatin with the ninhydrin assay. The
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ninhydrin stock solution was prepared by dissolving 70 mg of ninhydrin in 20 mL of
ethanol. Gelatin-G3.5 conjugates in very small amounts (1 or 2 mg) were dissolved in 1
mL of ethanol and further mixed with 1 mL of ninhydrin stock solution. The mixture
solution was heated to 90 °C for 5 minutes after which it was cooled down to 25ºC. The
concentration of amine groups ( [NH2], mg/mL) was determined at the wavelength of 570
nm based on the calibration curve, which was established using pure gelatin of known
concentrations. The standard curve for gelatin in ninhydrin is graphed in Figure 6.
Figure 6: Standard Calibration Curve of Gelatin (Ninhydrin Assay)
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3.4.2 1H-NMR Spectroscopy
1

H-NMR spectra of the synthesized polymers were recorded on a Varian

superconducting Fourier-transform NMR spectrometer (Inova-400). Deuterium oxide
(D2O, 99.9%) was used as the solvent. The chemical shift for D2O is 4.8 ppm. Post-
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processing was done using “Spin-Works” (free shareware) software courtesy of the
University of Manitoba, Canada.
3.4.3 Mechanical Property Testing
Dog bone-shaped samples were cut (1.85 cm-length x 0.6 cm-outer diameter x 0.3
cm inner diameter) with a punch die for mechanical testing. The punch was positioned on
the electrospun mat perpendicular to the mandrel’s axis of rotation. Six dogbones were cut
from each mat and the sample thickness measured using digital calipers. Uniaxial tests
were conducted using a Bionix 200 Mechanical Testing Systems with a 50N load cell. The
offset edges of the dog bone specimen were loaded into the metal grips of the machine and
tested at 10 mm/min until failure. Stress, strain, elastic modulus, peak load, and break
were calculated and reported from the TestWorks4 computer software program.
3.4.4 Scanning Electron Microscopy (SEM)
Fiber morphology and fiber diameter were observed under scanning electron
microscopy (SEM) employing a JEOL JSM-820 JE electron microscope with an
acceleration voltage of 15kV. Samples were cut from each scaffold and gold sputter
coated (Model 550; Electron Microscope Sciences) in preparation for scanning electron
microscopy. An SEM photograph of each sample was taken at 1700x magnification.
Thirty different fibers were measured using ImageTool 3.0 image visualization software
(shareware provided by UTHSCSA). The software was calibrated using the micron scale
bar of each photograph and average fiber diameter reported.
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3.4.5 Porosity Measurement
Porosity, expressed as the percentage of void to total volume, was determined using
the apparent volume method. The following equation was used to calculate porosity:

P  [1  (

Vg
)] 100
Va

Equation 1

Vg = mass of the scaffold / density of collagen (1.41 g/cm3)

Where:

Va = apparent volume of square section 1cm x 1cm x thickness
Sample thickness was measured using digital calipers. Three samples from each specimen
were used to determine the porosity of each scaffold.
3.4.6 Permeability Measurements
The permeability of three punches (12 mm diameter) from each electrospun mat of
each blend was measured using a meter developed by Scott Sell based on Ogston’s theory
of flow through systems of long thin rods.46
samples.

Water was the fluid utilized for testing the

Permeability, represented as the Darcy constant (τ), is calculated using the

following equation:



QD
tAp

Equation 2

where: Q=volume flowing through system, =fluid viscosity (0.89 cP),
D=scaffold diameter (12 mm),

A=cross-sectional area of scaffold ( r2),

p=applied pressure (i.e. gh= 1000 kg/m2 * 9.8m/s2* 1.5m(h); converted to
atmospheres).

t = time in seconds
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Pore size was calculated by using the permeability determined in Equation 2 and the
formula:

r  0.5093  

3.4.7

Equation 3
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Absorption and Water Swelling Behavior
The swelling ratio was used to evaluate the absorption properties of each dressing

type. The swelling ratio of each test membrane was determined by immersing the sample
in phosphate-buffered saline (PBS, pH 7.4) at room temperature. Subsequently, the weight
of the swollen membrane was determined by sandwiching the membrane between two
paper towels to remove excess water on the surface and weighed immediately. The
swelling ratio (Rsw) of each test sample in PBS was calculated as follows:

RSW  [

(Wf  Wi )
] 100
Wi

Equation 4

where: Wf denotes the weight of the test sample after swelling and Wi is its initial weight.
Three samples per gelatin-polymer blend were evaluated to determine water swelling
kinetics.
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3.4.8

In vitro Degradation
The in vitro degradability of each test sample was assessed as a measure of

physiologic degradation. The test samples were well immersed in PBS (pH 7.4) and
incubated at 37°C for 24h. After degradation, the test samples were centrifuged for 20 min
in deionized water, frozen, then lyophilized for 5 h and weighed. The ratio of weight loss
(RWL) due to in vitro degradation for each test sample was calculated using the formula:

RWL  [

(Wi  Wf )
]  100
Wi

Equation 5

where Wf denotes the weight of the test sample after in vitro degradation and Wi is its
initial weight. Three samples per gelatin-polymer blend were evaluated for this analysis.
Additionally, degradation was evaluated for 7 days by the above method; to evaluate
degradation rate for each hybrid.

3.4.9 Drug Release Kinetics of Doxycycline
Drug release kinetics were determined through dialysis of the drug in DI water.
Figure 7: Analytical Set-up for Drug Release Kinetics
Beaker
Dialysate
Dialysis bag
Sample

Stir bar
Stir Plate
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To study drug release kinetics, samples of each electrospun gelatin-polymer mat
were obtained, weighed and loaded into a dialysis tube. After the tubing was clamped at
one end, 20mL of PBS (pH 7.4) was added.

At least 50% of the total scaffold weight

was utilized and the remainder of the sample retained for replicate testing (to evaluate
accuracy and reproducibility).

The filtrate, 400mL of DI water, was added to three

separate beakers and heated to 37 °C. After heating to the set-point, the sample (dialysis
diskette) was immersed in each beaker. The 50/50 w/w gelatin-polymer blends were
evaluated at the same time, but in 3 different beakers. The 70/30 w/w gelatin-polymer
blends were tested in the same manner.

To evaluate the short-term drug release, samples

were collected at the following time intervals (in minutes): 2, 5, 7, 10, 15, 25, 35, 45, 60,
75, 90,120, 150, 180 and 240 for 15 samples. The absorbance value was recorded from the
UV-Vis spectrometer for each sample per hybrid at the cut-off wavelength of 190 nm.
After each measurement, the sample was re-injected into the beaker to keep the level of
filtrate constant. The observed absorbance value was referenced against the standard curve
of DC and the concentration of the drug was interpolated. Doxycycline was dissolved in
DI water at a concentration of 1 g/mL and scanned for the maximum absorbance on the
UV-Vis spectrometer. Figure 8 shows that the maximum absorbance for DC is at a cut-off
wavelength of 190 nm.

The standard curve of DC was developed using a cut-off

wavelength of 190 nm and is shown in Figure 9. The initial amount of DC was calculated
from the ratio of the sample weight divided by total scaffold weight equal to unknown DC
initial weight divided by total DC. The initial drug weight ranged from 2 to 5 mg per
sample.
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Figure 8: UV-Vis Scan of DC ( 1 g/mL)
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Figure 9: Standard Calibration Curve of DC (190 nm)
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Drug release over time was determined by calculating percent drug release. The
percentage of drug release was calculated as follows:

% DR  (

Ct
)  100
Ci

Equation 6

where Ct= concentration of drug released at time (t), and Ci = initial concentration of drug
in the sample. Initial drug concentration was calculated from the ratio of specimen weight
divided by total sample weight equal to the mass of DC divided by the total DC added to
the electrospinning solution. Initial concentration of DC per test specimen ranged from
0.04 to 0.05 mg/mL.

3.4.10 Statistical Analyses and Graphical Representations
Minitab Statistical analysis software was utilized to perform Analysis of Variance
(ANOVA), Analysis of Means (ANOM) and Tukey’s Test for Significance to determine
statistical differences (if any) between fiber diameter and the mechanical properties of peak
stress, modulus and breaking strain across different blend compositions and w/w ratios.
Analysis of variance is a statistical test that compares the variation within a group to the
variation among groups. A positive ANOVA indicates that the differences among groups
are more substantial than would be expected by chance alone. Analysis of means is a
graphical analog used for testing the equality of population means. MINITAB displays a
graph, similar to a control chart, highlighting group means that are different from the
overall mean. If differences among the sample groups were found, Tukey’s pair-wise
comparisons were done to determine which values were significantly different. Tukey’s
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method compares the means for each pair of group levels using an overall error rate that is
specified by the user. Results are presented as confidence intervals for the difference
between pairs of means. If an interval does not contain zero, the means are statistically
different, else accept the null hypothesis (means are the same). An alpha level of 0.05 was
selected for all statistical tests. Graphical representations were constructed using Microsoft
Excel 2003 and MINITAB.
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CHAPTER 4 Results and Discussion
4.1 Preparation and Characterization of G3.5-Gelatin Conjugates
EDC chemistry was used to conjugate gelatin to PAMAM G3.5 dendrimer (Figure
10).

A UV-Vis spectrophotometer scan of pure gelatin and PAMAM G3.5 yielded

overlapping peaks; which negates this analytical tool from confirming the synthesis.
Subsequently, verification of the conjugation of gelatin to G3.5 was indirectly determined
by measuring the remaining amine surface groups of gelatin with the Ninhydrin assay.
Ninhydrin reagent reacts with amino acids resulting in a purple colored solution.47 The
absorbance can be measured at the 570 nm wavelength on a UV-Vis spectrophotometer.
Per the standard curve for gelatin with ninhydrin reagent (Figure 3), a 1 mg/mL sample of
gelatin would have an absorbance value of approximately 0.1685.

Ninhydrin reagent

solution was added to a 1 mg/mL sample of the G3.5-gelatin conjugate; measured at 570
nm on the UV-Vis.

The measured low absorbance value of 0.027 resulted from the

decrease of the terminal amine groups –NH2 of the gelatin due to the coupling reaction.

Figure 10: Schematic of Reaction to Form an Amide Bond 48
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The Steglich esterification method of forming esters under mild conditions was
attempted to conjugate PAMAM G3.5 dendrimer to doxycycline (Figure 11). Steglich
esterification involves activating the carboxylic (-COOH) groups of the dendrimer with
DCC. After activation, DMAP is used as a catalyst. We were not successful in conjugating
DC to PAMAM G3.5. The hydroxyl groups of the DC were inaccessible; and could not be
used to form an ester bond with the carboxyl groups of the dendrimer
Figure 11: Schematic of Steglich Esterification to Form an Ester Bond 49

The conjugation of G3.5 to DC was not confirmed by 1H-NMR as shown in Figure 12
below. The peak for DC was not evident in the NMR image.
Figure 12: 1H -NMR of DC-PAMAM G3.5

The yield of the G3.5-DC reaction synthesis ranged from 35 to 45% in five replicates of
the reaction steps. Low yield can be attributed to product purification through dialysis.
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The dialysis tubing used in the purification process had a molecular weight cut-off
(MWCO) of 12000-14000. Doxycycline is small enough to escape through the pores. Due
to the poor yield of this reaction and inadequate reproducibility, other therapeutic drugs are
being explored in our laboratory.

Because we were not successful in the synthesis of

conjugating PAMAM G3.5 to DC, the drug release kinetics from the electrospun wound
dressings will be performed using encapsulation of DC in the spinning solution.
Two different PAMAM dendrimers, G3.5 and G4, were electrospun with gelatin to
evaluate scaffold morphology and mechanical properties. Three different concentrations
of dendrimer in gelatin were electrospun and evaluated. The G4 dendrimer/gelatin mats
showed significantly larger fiber diameters, with means ranging from 3.4 to 4.2 m. and
displayed a flattened and oblong cross-section. The G3.5 dendrimer /gelatin mats had
smaller diameter fibers, ranging from 1.8 to 2.5 m on average.

The G3.5

dendrimer/gelatin hybrids exhibited a cross-section similar to pure electrospun collagen
and gelatin. The full generation PAMAM dendrimers have a positive charge; whereas the
G3.5 dendrimers have a negative charge. These charge differences influence the electrical
field during electrospinning, increasing the charge differential thereby altering the fiber
diameter. It is believed that solvent evaporates more readily from the positively charged
polymer solution, forming a skin layer on the exterior. After the fiber is formed, the outer
skin collapses forming an elongated, oval cross-section. These data are shown in Figures
13 and 14. Electrospun scaffolds containing PAMAM G3.5 dendrimer had the desired
morphology and fiber diameter to resemble native ECM and will be further evaluated.
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Figure 13: SEM of PAMAM G3.5 and G4.0 Scaffolds
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G4.0C

G3.5A:4mg, G3.5B:6mg, G3.5C:10 mg, G4.0A:4mg, G4.0B:6mg, G4.0C:10 mg,
scale bar = 3 m
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Figure 14: Fiber Diameter of PAMAM G3.5 and G4.0 Scaffolds
Fiber Diameter by Dendrimer/Weight Percent
G3.5 vs G4.0
G4.0C

4

Type

G4.0B

3

G4.0A

4

G3.5C

3

G3.5B

2

G3.5A

2
0

1

2

3

4

5

6

7

8

9

10

FibrDiam
Fiber Diameter measured in micrometers

An additional study was done to determine if DC drug encapsulation impacts
spinnablity and fiber diameter. Conjugates of G3.5 and gelatin, along with pure gelatin
solution containing DC were mixed in solution with TFE and electrospun. A comparison
of means for strain, stress and Modulus are summarized in Table 9.

Mechanical strength,

as measured by stress and strain, is significantly different for the scaffold mats of G3.5gelatin conjugates (at 0.10 MPa, 0.16 mm/mm) versus pure gelatin (at 1.40 MPa, 0.06
mm/mm) or gelatin with encapsulated DC (at 0.96 MPa, 0.06 mm/mm).

The

encapsulation of DC into the scaffold did not significantly impact mechanical properties.
The statistical difference of significantly lower stress in the scaffolds with G3.5-gelatin
conjugates is attributed to the smaller diameter fibers.50
dissolved in aqueous environments.

Gelatin scaffolds are easily

Synthetic polymers were added to increase

mechanical strength and reduce dissolution rates; and further characterize scaffolds.

42

Table 9: Mechanical Properties of Electrospun Gelatin

Scaffold

Strain (mm/mm)

Stress, (MPa)

Modulus, MPa

Gelatin

0.06  0.01

1.400.58

37.59  16.09

Gelatin+DC

0.06  0.02

0.960.52

26.09  10.44

Gelatin-G3.5

0.16  0.04*

0.100.02*

1.13  0.21*

Comparison of Means – Means with an asterisk (*) are statistically different
( =0.05, Pr < 0.001)
4.2 Gelatin/dendrimer Hybrid Morphology
The SEM photographs were similar for all of the polymer gelatin blends; and
similar to electrospun gelatin as shown in Figure 15. Gelatin and the synthetic polymers
were successfully electrospun into uniformly distributed fibrous scaffolds (Figure 16). All
samples displayed homogenous fibrous structures when observed via SEM.
Figure 15: SEM of Electrospun Gelatin

Scale bar: 2 m, 1.05 kX magnification
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Figure 16: SEM Micrographs of Polymer Blends

A

B

C

D

E

F

A:50/50 PCL/gel,B:70/30 PCL/gel,C:50/50 PGA/gel,D:70/30 PGAgel,E:50/50 PLGAgel,F:70/30 PLGA gel
Scale bars: A=10 m, B=3 m, C=10 m, D=10 m, E=10 m, F=2 m
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The scaffold morphology, represented by fiber and pore diameter and visual
observations, is similar to previously reported data of electrospun gelatin scaffolds.18,44
The fiber diameter and mechanical properties are summarized in Table 10 and graphically
represented in Figure 17. Fiber diameters varied with the varying w/w ratio of gelatin to
polymer and polymer type. Much of the previously published electrospun data on gelatin
show that increasing gelatin concentration increases fiber diameter.
increasing fiber diameter causes an increase in mechanical strength.

Additionally,

50

Table 10: Summary of Mechanical Properties.
Fiber Diameter
( m)

Stress
(MPa)

Modulus
(MPa)

Strain
(mm/mm)

Break
Energy
(N-mm)

Gelatin
(Control)

2.2 ± 0.1

1.6 ± 0.3

22.1 ± 7.3

0.06 ± 0.02

0.11 ± 0.04

PCL/gel
50/50

2.0 ± 0.7

2.8 ± 0.8

41.9 ± 9.3

0.09 ± 0.02

0.32 ± 0.07

PCL/gel
70/30

1.9 ± 0.9

2.3 ± 0.6

19.0 ± 5.2

0.39 ± 0.09

1.06 ± 0.54

PGA/gel
50/50

1.7 ± 0.9

*0.7± 0.3

18.2 ± 9.7

0.06 ± 0.01

0.13 ± 0.07

PGA/gel
70/30

*2.7 ± 1.1

*3.7± 0.7

36.8 ± 13.9 *2.66 ± 0.35

*39.17 ±0.95

PLGA/gel
50/50

1.8 ± 0.8

0.6 ± 0.3

9.2 ± 6.4

0.16 ± 0.05

0.15 ± 0.05

PLGA/gel
70/30

*1.3 ± 0.8

*4.6 ± 1.0

*47.5 ± 13.8

*1.84± 0.30

*43.62 ±0.38

Statistically different means are marked (*)
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Figure 17: Graphical Summary of Fiber Diameter, Stress, and Strain
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PGA/gel
70/30

In this study, the gelatin concentration and synthetic polymer concentration were
varied together. Therefore, determining the impact of changes in gelatin concentration on
the mechanical properties was confounded with the changes in synthetic polymer
concentration and type.
Fiber diameter of electrospun gelatin has been shown to be a function of solution
concentration as concluded in our previous work. With the exception of the PGA/gel
70/30 blend (significantly larger fiber diameter) and PLGA/gel 70/30 blend (significantly
smaller), fiber diameter was not statistically different.

Additionally, the inclusion of DC

in the spin solution had no effect on pore area or fiber diameter when comparing the mat to
100% gelatin as the control.

The mean fiber diameter ranged from 1.3 um to 2.7 um with

a pooled standard deviation of 0.9 (Appendix A).
using ANOVA in Minitab.

Statistical differences were analyzed

The fiber diameters for PGA/gel 50/50 blend were

significantly smaller than the PGA 70/30 blend; however, the opposite was true in
comparing PLGA/gel 50/50 and 70/30 w/w preparations. The fiber diameter for the latter
was significantly smaller.

Possible contributors are the change in synthetic polymer

weight affecting the spin solution viscosity; thus impacting fiber diameter.
The ANOVA and Tukey’s comparisons confirmed graphical observations of stress
by type and w/w blend ratios. Mean stress is statistically higher in the 70/30 PLGA/gel
mat, which is significantly higher than the 70/30 PGA/gel blend; which is statistically
higher than all other blends including the gel control.

The larger diameter fibers in the

PGA/gel 70/30 blend is the main contributor the higher stress; as larger diameter fibers are
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stronger in tension.

All variables of the fabrication process were controlled (i.e. the

distance to mandrel, spinning voltage, mandrel rotation and geometry were held constant).
Therefore the changes in fiber diameter and mechanical properties are solely due to the
polymer type and weight ratios of gel to polymer.
The mean strain for the study mats ranged from 0.05 to 2.66 mm/mm with a pooled
standard deviation of 0.18 (Appendix).

The strain for PGA/gel 70/30 and PLGA 70/30

blends were significantly different from the strains exhibited in the other blends, including
the electrospun gel control, and each other.

This may be large due to similar physical and

chemical properties of PGA and PLGA.
Regardless of the mechanical property measured, the greater the percentage of
synthetic polymers PGA and PLGA in the blend, the more extreme the values for stress
and strain. Both PGA and PLGA at the higher weight ratios showed greater mechanical
strength, as measured by stress and break energy when compared to pure electrospun gel as
the control. This infers that the addition of PGA and PGLA will yield stronger electrospun
mats. One of the main reasons for blending and electrospinning the synthetic polymer with
gelatin was to increase the mechanical strength and aqueous stability of the dressing. The
encapsulation of dendrimer and DC in the spinning solutions did not significantly impact
the stress and strain properties of the scaffold.
4.3 Porosity, Permeability and Swelling Behavior
The electrospun polymer matrices were evaluated for fluid and gas flow capability
to confirm their viability as a wound dressing. The data is summarized in Table 9 and
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graphically represented in Figures 18 through 21. Fluid and gas exchange is essential to
ensure adequate wound healing. Cell migration, oxygen and moisture are essential to
ensure tissue regeneration in chronic wounds. The ultimate test to determine the success of
the proposed dressing is dependent on its ability to mimic native ECM and allow cells to
infiltrate the construct, migrate through its thickness and proliferate as ECM is essential to
remodeling.51

Tissue regeneration is also facilitated by adequate nutrient flow, gas

exchange and maintenance of a moist wound bed for proper healing. 52

Scaffold pore

diameter, porosity, permeability and swelling and degradation behavior were evaluated as
a means to measure its suitability and ability to ensure adequate flow of oxygen into the
wound bed; while simultaneously maintaining a moist wound bed.
Table 9: Summary of Gel-Polymer Matrix Fluid Flow Capability
Pore Diameter

Porosity

Permeability

RSwelling

RDegradation

( m)*

(%)

(D)

(%)

(%)

PCL/gel
50/50

0.28 ± 0.01

87.4 ± 0.2 0.0028 ± 0.0003 345.6 ± 10.7

28.3 ± 8.3

PCL/gel
70/30

0.25 ± 0.11

86.3 ± 1.0 0.0024 ± 0.0015

296.3 ± 8.6

10.6 ± 1.2

PGA/gel
50/50

0.31 ± 0.85

86.7 ± 0.7 0.0036 ± 0.0014 520.3 ± 41.3

30.4 ± 14.6

PGA/gel
70/30

0.23 ± 0.04

82.9 ± 2.2 0.0024 ± 0.0008 294.6 ± 41.7

45.0 ± 7.1

PLGA/gel
50/50

0.39 ± 0.02

89.8 ± 1.8 0.0048 ± 0.0021 347.1 ± 34.9

10.0 ± 9.3

PLGA/gel
70/30

0.23 ± 0.39

85.2 ± 0.7 0.0024 ± 0.0007 256.7 ± 7.1

15.5 ± .2

Pore Diameter calculated from Equation 6 using permeability(*)
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Porosity is a measure of the amount of void space in the electrospun scaffold and
values are shown in Figure 18. The porosity ranged from 83 to 89%. The lowest porosity
value was supported by SEM depictions of the 70/30 PGA/gel polymer blend. The scan
shows minimal pores; which is also confirmed by pore diameter as calculated by the Darcy
permeability. None-the- less, these levels are suitable as a TE construct as they are in the
acceptable 70-90% range for adequate gas and nutrient exchange to underlying cells.
Figure 18: Gel/Polymer Dressing - Porosity
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Permeability is a measure of the ease of flow through a scaffold. The permeability
ranged from 0.0024 to 0.0048 Darcy.

The lowest porosity value was supported by SEM

micrograph of the minimal pore diameter. Permeability trended with porosity, in that the
50/50 PLGA/gel mat was the most porous and showed significantly higher permeability.
Permeability measurements are depicted in Figure 19.
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Figure 19: Gel/Polymer Dressing - Permeability

0.0070

Permeability (D)

0.0060
0.0050
0.0040
0.0030
0.0020
0.0010
0.0000
PCL/gel
50/50

PCL/gel
70/30

PGA/gel
50/50

PGA/gel
70/30

PLGA/gel
50/50

PLGA/gel
70/30

Water swelling results are presented in Figures 20 and 21. The swelling rate was
found to be a function of polymer type and weight ratio of each individual component of
the gelatin/polymer hybrids. For all the gel-polymer blends, the swelling rate showed a
maximum value at the 30 minute time interval; thereafter reaching a plateau.
The 50/50 PLGA/gel mat showed the highest porosity (openness) and the highest
permeability (ease of flow), as the two are interrelated. As expected, the least amount of
swelling of the fibers occurred in this mat as a result of the increased void space, where
fibers are non-existent. Likewise, the 70/30 PLGA/gel mat was one of the least porous
structures and thus had the highest swelling rate for the two hour evaluation. The swelling
ratios were higher for the 50/50 w/w versus 70/30 w/w blends, which is a result of the
swelling behavior of the gelatin. These data are shown in Figures 18 and 19.
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Figure 20: Gel/Polymer Dressing – Swelling Rate
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Figure 21: Gel/Polymer Dressing – Swelling Behavior
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The synthetic polymers used in this study, PCL, PGA and PLGA, are susceptible to
hydrolysis at various rates. The rate and extent of hydrolysis is heavily dependent on the
hydrophilicity of the individual polymer and any co-polymers. The more hydrophilic the
polymer, the more aggressive the hydrolysis will be.
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The blending of the synthetic

polymers with gelatin as a co-polymer impacts the hydrophilicity of the electrospun
polymer matrix and their electrospinning conditions since intrinsic viscosity changes.
Subsequently, the degradation rates will also be impacted. Based on the physical and
chemical properties of the synthetic polymers evaluated in this study, PGA should have the
faster rate of swelling, as it is the most hydrophilic of the three. Figure 22 is a depiction
of the bulk degradation sequence for the synthetic polymers used in this study.
Figure 22: Theoretical Bulk Degradation Sequence

PGA

PLGA

PCL

2- 4 weeks--------------- 6 months-----------------------12 months

> 2 years

In our evaluation, the 50/50 gelatin/polymer blends degraded at a much faster rate. This is
mostly due to the higher amount of gelatin; thus faster hydrolysis in comparison to the
higher amouNt of synthetic polymer. The synthetic polymer blends with PCL showed the
least amount of degradation, as PCL can take up to 2 years to degrade in-vivo. Regardless
of the blend ratio, PLGA degraded at a significantly higher rate than the other two
polymers (PCL and PGA); which did not follow the theoretical prediction. The 24-hour
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degradation is shown in Figure 23. Note that the scaffold with the highest permeability
and porosity, showed the fastest degradation.
Figure 23: Gel/Polymer Dressing – Degradation
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The degradation results were not consistent with the water swelling results, but
were consistent with the observed trend for permeability. Bulk degradation, considered
homogenous hydrolysis, occurs when the diffusion of water into the polymer matrix is
faster than the overall rate of hydrolysis.54

As water diffuses into the matrix and cleaves

the ester bonds, erosion of the fibers occurs leading to a decrease in mass. For PLGA, the
degradation time is dependent on the monomer ratio of lactide to glycolide. The more
glycolide monomers, the more hydrophilic the co-polymer.

PLGA 85:15 is less

hydrophilic than PGA and should have degraded at a slower rate. However, the higher
porosity and permeability in the PLGA/gelatin 50/50 w/w electrospun mat is credited as a
major contributor to the faster degradation, since degradation rate is also dependent on the
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morphology, porosity and permeability. Degree of crystallinity also affects degradation.
The greater the degree of crystallinity, the slower the degradation.

Poly (lactic-co-

glycolic) acid is amorphous which results in a faster in vitro degradation rate.
4.4 Drug Release Kinetics
It has been shown that the release of active drugs as function of time can be
measured by means of diffusion of the drug from a porous membrane.

Diffusion

controlled drug release was achieved by using dialysis tubing loading with the sample,
containing the drug and PBS as the dialysate. Doxycycline was measured when the drug
diffused from higher concentration (inside the porous membrane) to the filtrate, which in
our study was deionized water. Figure 24 is a graphical representation of the drug release
of DC over time. We observed that an increase in the weight of the synthetic polymer
resulted in the lower amount of released drug.

In both ratios, regardless of polymer type,

controlled release of the drug is apparent. The release, however is short-lived, reaching a
plateau within two hours, with no significant release thereafter. We hypothesize that the
plateau is due to hydration of the gelatin and synthetic polymers causing the fibers to
swell, thus increasing their fiber diameters and subsequently reducing pore size. The
reduction in pore size traps the drug, sequestering it inside the interior of the mat.
Extending the drug release studies for long-term evaluation (days to weeks) is required to
confirm our supposition that as the mat swells to its maximum size; the drug release
kinetics will plateau; and then increase as the PGA, PCL and PLGA continue to hydrolyze
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thus releasing more of the drug. This degradation will lead to additional release of the
entrapped drug (i.e. residual drug).
Figure 24: Drug Release Kinetics (Synthetic Polymer/Gelatin blends)
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Gelatin is soluble in water; whereas the synthetic polymers used in this study have
no to minimal solubility in water. The burst in drug release is attributed to the surface
degradation and dissolution of the gelatin. The higher release rate of the 50/50 w/w blends
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in comparison to the 70/30 w/w blends is mainly due to the higher amount of gelatin;
therefore faster degradation (i.e. hydrolysis) of the matrix. As the gelatin dissolves, the
drug is released from the interior of the mat. The drug release profile for the 50/50 w/w
blends closely followed the degradation rate profile. As noted previously, PGA had more
mass loss in 24 hours and over a 7 day time-frame. The drug release of DC was also
higher for the 50/50 w/w PGA/gelatin blend. More than 50% of the drug was released;
which may indicate that some of the polymer, however minimal, hydrolyzed as well. An
alternative means of evaluation, for example High Performance Liquid Chromatography
(HPLC), should be employed in lieu of measuring the absorbance to determine the
concentration of the released drug. High Performance Liquid Chromatography will allow
more accurate measurements of drug concentration as it can better partition different
components of the blend based on their affinity. 55-56

An article by S.M. Sunaric, et al.,

confirms that the peak absorbance for DC is measured at approximately 270 nm and 360
nm. 57

As indicated in Figure 8, two secondary peaks occur at approximately 270 nm and

360 nm; however a wavelength of 190 nm was used to measure released drug (DC) since
the maximum absorbance was observed at this point.

Sunaric’s research evaluated

physiologic degradation of DC in samples with concentrations of DC ranging from 2.97 to
17.78 g/mL. We used UV-Vis to measure concentrations of DC within the same range.
According to British Pharmacopoeia, the official method for DC determination is liquid
chromatography with UV detection. This further confirms the necessity of our future work
to develop an HPLC method for analysis of DC released from our polymer scaffolds.
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4.5 Conclusions
Our work demonstrated that gelatin/dendrimer hybrids could be formed using full
and half generation dendrimers and electrospun with stabilizing synthetic polymers and the
antibiotic Doxycycline.

The half generation dendrimer produces significantly smaller

fibers that resemble electrospun collagen and gelatin (fabricated using the same operating
parameters and conditions).

Three different stabilizing polymers were electrospun with

gelatin and PAMAM G3.5 dendrimer to form the hybrids. Synthetic polymer type and
weight ratio was shown to affect the permeability, porosity, mechanical properties and
water swelling and degradation of the electrospun mats.
The increased weight addition of PCL, PGA and PLGA to the gelatin/dendrimer
hybrids decreased the porosity and permeability of the electrospun mat; corresponding to
decreased fiber diameters and pore sizes. Theoretically, decreased fiber diameter should
result in decreased mechanical stress, however, the stress values for the synthetic polymers
far exceeds that of gelatin. Subsequently, the greater the amount of synthetic polymer, the
higher the stress and strain values of mats. As proven in statistical analyses and graphical
representations, the greater the weight ratio of synthetic polymer, the higher stress and
strain levels the fibers could withstand.
Poly(glycolic acid) is more hydrophilic than PCL and PLGA.

As such, the

observed degradation and swelling ratio of the PGA containing mats versus the other two
was at a much faster rate.

This faster degradation resulted in a higher release of the drug

in the time-frame analyzed. Drug release kinetics for all compositions showed a controlled
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release over a four hour time frame.

A statistical evaluation of the drug release profile for

each polymer mat was not performed.
The success of fabricating an electrospun gelatin/dendrimer hybrid that can be
utilized as a wound dressing with targeted and controlled drug release was demonstrated
and achieved in this study.

The synthetic polymer type and amount in the

gelatin/dendrimer hybrids can be varied to influence the morphology, mechanical
properties, swelling behavior and degradation, thus impacting its drug release kinetics.
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CHAPTER 5 Summary and Future Work
5.1 Summary
In the past few years, significant effort has been devoted to researching and
developing nanomedicine and nanotechnology for controlled and targeted drug delivery.
Presently, biomaterials and drug development has shown an increased focus on
formulating therapeutic agents in biocompatible nanocomposites, like liposomes, micelle
systems, nanocapsules and polymer conjugates, that are sub-micron sized.

Advances in

localized and tissue-specific delivery of small particles, like anticancer drugs, gene vectors,
antimicrobials and other therapeutic agents, improve drug efficacy and decrease toxicity,
and reduce drug side-effects.
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The utilization of dendrimers as nano-sized drug

carriers is expanding. Dendrimer drug carriers can be easily tailored to deliver both
hydrophilic and hydrophobic drugs effectively and efficiently. Dendrimers exhibit surface
charges that can be exploited to control pH and temperature sensitivity, as well as
electrospun product characteristics.

However, the research in developing

gelatin/dendrimer hybrids for use as a wound dressing is limited.
Gelatin must usually be electrospun and cross-linked to acquire the mechanical
properties and suitable characteristics as a TE scaffold. 60 In this study, gelatin/dendrimer
and synthetic polymer matrices were formed by electrospinning and characterized to
quantify their physical morphology, gas and nutrient flow capability, as well as swelling
behavior, degradation rate and drug release kinetics.

The gelatin/dendrimer hybrids that

were fabricated show promise as a bioactive dressing to treat chronic wounds. They are
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highly adaptable, and exhibit the properties necessary to maintain a moist wound bed to
promote wound healing. Additionally, the controlled and targeted release of Doxycycline
has the potential to facilitate wound healing by inhibiting MMPs that degrade the
reconstituted ECM.
The polymer matrix can be engineered to control wound bed moisture by altering
synthetic polymer type and weight ratio. Leveraging the amount of gelatin allows better
swelling behavior and moisture retention. Wound bed moisture is critical to promote
wound healing and ensure adequate nutrient and gas exchange, as well as cell migration,
within the wound.

The electrospun mat also mimics the native ECM, which theoretically,

should foster cell adhesion, migration and subsequently proliferation.

The attractive

features and easy adaptability of the gelatin/dendrimer hybrid developed in this study will
enable its application as a bioactive dressing to promote wound healing.

5.2 Future Work
This study attempted to characterize the physical properties, swelling, degradation
and drug release profiles of gelatin/dendrimer hybrids for biomedical applications as a
wound dressing.

Doxycycline has been shown to inhibit MMPs, which are at excessive

levels in chronic ulcers. However, this activity was not evaluated in this study. Studies
designed to evaluate the impact of DC, released to the wound bed, will be conducted in our
future work. Assays to measure the level of degradative enzyme contained in wounds
covered by the proposed gelatin/hybrid and those using a control will be evaluated. In

61

vitro studies of the dressing’s ability to provide a bacteria-free environment to facilitate
wound healing will also be conducted.
The wound healing process is complex and involves interactions of various cells
and matrix components to create a provisional matrix, a platform by which cells can
migrate and adhere to, leading to eventual closure of the wound. Wound closure, i.e. reepithelialization, involves the controlled migration of fibroblasts and keratinocytes.
Recent research has shown that the inclusion of basic fibroblast growth factor (FGF) and
transforming growth factor beta (TGF-) accelerates cell growth and wound healing.
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Human skin equivalents have been utilized to assess the acceleration of wound healing and
the impact of additives like growth factors and proteins like collagen in wound dressings.
In a study by Schneider and Wang, the rate of wound contraction was successfully
measured and accelerated by the inclusion of epidermal growth factor (EGF) in electrospun
silk fibroin scaffolds.
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Cell interaction and proliferation studies were not conducted to

assess the bioactivity of the dressing and its ability to facilitate or accelerate wound
healing. Expanding this project to include in vitro and in vivo studies evaluating the
migration and proliferation of fibroblasts and keratinocytes is a necessary milestone in our
future work.
Chronic wounds including diabetic foot ulcers, pressure ulcers, and venous leg
ulcers have been shown to have abundant biofilm communities. In a study by James, et al.,
chronic and acute wounds were evaluated for biofilms and the bacterial microorganisms
inhabiting these wounds were characterized. 63 Sixty-percent (60%) of the chronic wound
specimens that were evaluated by this group contained biofilms, compared to only 6% of
62

the acute wound specimens. Further, molecular analyses of chronic wound specimens
examined in their evaluation revealed diverse polymicrobial communities and the presence
of bacteria, including strictly anaerobic bacteria, not revealed by culture.
Bacterial biofilm prevalence in chronic wounds adds further complexity in trying to
accelerate wound healing. Very few antibiotics have been shown to effectively mitigate or
eradicate biofilms.
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Bacterial vaginosis and urinary tract infections show significant

biofilm formation, which contributes to a high rate of recurrence and multiple treatments to
effect resolution. The antimicrobials, fleroxacin, ampicillin and gentamicin were found to
effectively eliminate a lactose-negative, streptomycin-resistant uropathogenic strain of
Escherichia coli in a study conducted by Morck, et al.
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Fleroxacin eliminated E. coli

from the catheter surfaces and from tissues adjacent to the catheter. The ability of
fleroxacin to effectively eliminate biofilm bacteria from catheter surfaces and adjacent
tissues shows promise as a potential drug for inclusion in the gelatin/dendrimer hybrid to
treat chronic wounds.
We have successfully fabricated and characterized gelatin/dendrimer hybrids for
use as a potential wound dressing. Our future work focuses on the cell interaction and
bioactivity of the gelatin/dendrimer hybrids. Gentamicin, doxycycline and fleroxacin will
be encapsulated and/or conjugated to the gelatin/dendrimer hybrids and their efficacy in
mitigating biofilm formation in chronic wounds is also a major focus in our future work.
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Appendix
One-way ANOVA: Stress versus Blend
Analysis of Variance for Stress
Source
DF
SS
MS
Blend
6
80.313
13.385
Error
35
13.531
0.387
Total
41
93.844

Level
gel(con)
PCLGel55
PCLGel73
PGAGel55
PGAGel73
PLGAGl55
PLGAGl73

N
6
6
6
6
6
6
6

Pooled StDev =

Mean
1.5622
2.7703
2.2948
0.7168
3.7103
0.6157
4.6003

StDev
0.2947
0.7967
0.5554
0.3456
0.6732
0.2645
1.0167

0.6218

F
34.62

P
0.000

Individual 95% CIs For Mean
Based on Pooled StDev
----------+---------+---------+-----(--*---)
(--*---)
(--*---)
(---*--)
(---*--)
(--*---)
(---*--)
----------+---------+---------+-----1.5
3.0
4.5

Tukey's pairwise comparisons
Family error rate = 0.0500
Individual error rate = 0.00356
Critical value = 4.42
Intervals for (column level mean) - (row level mean)
gel(con)

PCLGel55

PCLGel73

PGAGel55

PGAGel73

PCLGel55

-2.3301
-0.0862

PCLGel73

-1.8546
0.3893

-0.6465
1.5975

PGAGel55

-0.2766
1.9673

0.9315
3.1755

0.4560
2.7000

PGAGel73

-3.2701
-1.0262

-2.0620
0.1820

-2.5375
-0.2935

-4.1155
-1.8715

PLGAGl55

-0.1755
2.0685

1.0327
3.2766

0.5572
2.8011

-1.0208
1.2231

1.9727
4.2166

PLGAGl73

-4.1601
-1.9162

-2.9520
-0.7080

-3.4275
-1.1835

-5.0055
-2.7615

-2.0120
0.2320
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PLGAGl55

-5.1066
-2.8627

One-way ANOVA: Strain versus Blend
Analysis of Variance for Strain
Source
DF
SS
MS
Blend
6
40.7154
6.7859
Error
35
1.1048
0.0316
Total
41
41.8203

Level
gel(con)
PCLGel55
PCLGel73
PGAGel55
PGAGel73
PLGAGl55
PLGAGl73

N
6
6
6
6
6
6
6

Pooled StDev =

Mean
0.0545
0.2878
0.0912
0.0567
2.6607
0.1612
1.8353

StDev
0.0136
0.0910
0.0221
0.0153
0.3479
0.0534
0.2965

0.1777

F
214.97

P
0.000

Individual 95% CIs For Mean
Based on Pooled StDev
--+---------+---------+---------+---(-*-)
(-*)
(-*-)
(-*-)
(-*-)
(-*-)
(-*-)
--+---------+---------+---------+---0.00
0.80
1.60
2.40

Tukey's pairwise comparisons
Family error rate = 0.0500
Individual error rate = 0.00356
Critical value = 4.42
Intervals for (column level mean) - (row level mean)
gel(con)

PCLGel55

PCLGel73

PGAGel55

PGAGel73

PCLGel55

-0.5539
0.0873

PCLGel73

-0.3573
0.2839

-0.1239
0.5173

PGAGel55

-0.3228
0.3184

-0.0894
0.5518

-0.2861
0.3551

PGAGel73

-2.9268
-2.2856

-2.6934
-2.0522

-2.8901
-2.2489

-2.9246
-2.2834

PLGAGl55

-0.4273
0.2139

-0.1939
0.4473

-0.3906
0.2506

-0.4251
0.2161

2.1789
2.8201

PLGAGl73

-2.1014
-1.4602

-1.8681
-1.2269

-2.0648
-1.4236

-2.0993
-1.4581

0.5047
1.1459
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PLGAGl55

-1.9948
-1.3536

One-way ANOVA: FibrDiam versus Blend
Analysis of Variance for FibrDiam
Source
DF
SS
MS
Blend
5
29.383
5.877
Error
174
130.342
0.749
Total
179
159.724

Level
PCLgel55
PCLgel73
PGAgel55
PGAgel73
PLGAgl55
PLGAgl73

N
30
30
30
30
30
30

Mean
2.0340
1.8980
1.7330
2.6623
1.7890
1.3167

Pooled StDev =

StDev
0.7261
0.9277
0.8528
1.0652
0.7689
0.8084

0.8655

F
7.84

P
0.000

Individual 95% CIs For Mean
Based on Pooled StDev
----+---------+---------+---------+-(----*----)
(-----*----)
(----*----)
(----*-----)
(----*----)
(----*----)
----+---------+---------+---------+-1.20
1.80
2.40
3.00

Tukey's pairwise comparisons
Family error rate = 0.0500
Individual error rate = 0.00441
Critical value = 4.08
Intervals for (column level mean) - (row level mean)
PCLgel55

PCLgel73

PGAgel55

PGAgel73

PCLgel73

-0.5087
0.7807

PGAgel55

-0.3437
0.9457

-0.4797
0.8097

PGAgel73

-1.2730
0.0164

-1.4090
-0.1196

-1.5740
-0.2846

PLGAgl55

-0.3997
0.8897

-0.5357
0.7537

-0.7007
0.5887

0.2286
1.5180

PLGAgl73

0.0726
1.3620

-0.0634
1.2260

-0.2284
1.0610

0.7010
1.9904
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PLGAgl55

-0.1724
1.1170

One-way ANOM for FibrDiam by Blend

2.5

Mean

2.28695

2.0
1.9055

1.52405

1.5

PCLgel55

PCLgel73

PGAgel55

PGAgel73

Levels of Blend
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PLGAgl55

PLGAgl73
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